May 2026 Research Update

Across these studies, researchers tested ways to detect disease-related misfolded proteins (especially alpha-synuclein) and signs of nerve-cell injury using samples from skin, spinal fluid, or blood. Overall, the pattern was that single tests could be strong in one situation but weaker in another, while combining different markers looked more informative than relying on one marker alone. Several studies were exploratory or modest-sized, so how well these tests work across many clinics and early in disease remains uncertain. [1] [2] [3] [4]

In one prospective study that included external validation, a combined approach using skin testing for alpha-synuclein and tau, plus a blood marker of nerve-cell injury (neurofilament light chain), improved separation among Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and controls compared with any single marker. In that study, the blood marker helped separate multiple system atrophy from Parkinson's disease, and combining markers improved overall diagnostic discrimination. [1]

A multicenter study comparing two spinal-fluid alpha-synuclein seed amplification assay set-ups found that results for multiple system atrophy depended strongly on which lab condition was used. One condition did not detect multiple system atrophy at either site, while the other detected it with variable sensitivity and specificity, and agreement between the two methods was low for multiple system atrophy. This highlights that the exact assay approach can change whether multiple system atrophy is detected. [2]

Two other exploratory approaches aimed to increase specificity for synuclein-related diseases or multiple system atrophy. One study reported that disease-related alpha-synuclein could be detected from blood using neuron-derived extracellular vesicles and a seed amplification method, separating synucleinopathy patients from healthy controls without false positives in their dataset. Another study proposed a different spinal-fluid target, TPPP/p25 amyloid seeds, and reported that its seed amplification assay could differentiate multiple system atrophy from Parkinson's disease and other neurodegenerative diseases. [3] [4]

For patients and caregivers, this body of research mainly signals that lab-based tests for misfolded proteins are moving beyond single-sample, single-marker approaches, and that test performance can depend on the exact lab method used. These studies do not establish a single definitive test for routine diagnosis yet, and larger, real-world validation across many centers and disease stages is still needed. For now, the results are best viewed as background research that may shape future diagnostic tools and clinical trials, rather than something that immediately changes current testing everywhere.

Across imaging, wearable sensors, and voice analysis, these papers explored objective signals that might help distinguish multiple system atrophy (especially the parkinsonian subtype) from Parkinson's disease, or track disease-related brain changes. The overall pattern was that multiple system atrophy showed differences in specific brain regions or movement features that could be measured quantitatively, but many studies were moderate-sized or exploratory and lacked pathology confirmation. Some work focused on making tests more practical, such as shorter scan protocols or automated speech processing. [5] [6] [7] [8] [9] [10] [11] [12] [13]

Several imaging studies reported brain differences that helped separate multiple system atrophy from Parkinson's disease. A quantitative MRI approach measuring brain iron found higher iron in the globus pallidus and substantia nigra in multiple system atrophy than in Parkinson's disease and controls, and in a small follow-up group these measures increased over 12 months. Another MRI-based study using free-water imaging in cholinergic brain pathways found higher free-water in multiple system atrophy than in Parkinson's disease and controls, with one pathway showing the best discrimination between multiple system atrophy and Parkinson's disease (AUC 0.786). [9] [8]

Other studies focused on differentiating Parkinson's disease from the parkinsonian subtype of multiple system atrophy using functional or ultrasound-based imaging and movement testing. A resting-state functional MRI study reported lower activity measures in several brain regions in Parkinson's disease compared with multiple system atrophy-parkinsonian type, and one right cerebellar measure distinguished the two groups with an AUC of 0.90 in that dataset. A transcranial ultrasound plus MRI fusion method outperformed traditional ultrasound metrics for distinguishing Parkinson's disease from multiple system atrophy-parkinsonian type, with one substantia nigra measure reporting an AUC of 0.82 for that comparison. [7] [5]

Wearable-sensor gait testing and speech-signal analysis were also evaluated as practical tools. In gait analysis, hip range of motion during a specific timed task best separated multiple system atrophy-parkinsonian type from Parkinson's disease, with cross-validated AUC values above 0.70. For speech, one study developed an automated deep-learning method to segment rapid syllable repetition accurately across neurological diseases, while another study found that certain speech spectrum features differed by specific disease and dysarthria type, suggesting speech measures may be more useful for distinguishing particular diseases than for grading overall severity. [6] [12] [13]

Two PET (positron emission tomography) approaches aimed to measure brain changes related to multiple system atrophy. One feasibility study suggested a shorter static PET scan window could still detect neuroinflammation-related signals in multiple system atrophy with good agreement to longer dynamic methods. Another translational study reported first-in-human imaging with a tracer designed to bind alpha-synuclein aggregates, showing detectable brain binding in patients with multiple system atrophy and Parkinson's disease after extensive lab and animal validation. [10] [11]

For patients, these studies show that researchers are testing multiple objective ways to support diagnosis when symptoms overlap, including MRI markers (iron and brain-tract changes), PET scans, ultrasound-MRI fusion, wearable gait measures, and computer-based speech analysis. Most of this work is not yet a single standardized test, and many results come from single-center or exploratory studies that need replication across different hospitals and scanners. Some efforts, like shorter scan protocols and automated speech processing, matter mainly as groundwork to make future testing more consistent and less burdensome.

Across these studies, progression and survival in multiple system atrophy (MSA) were most consistently connected to how quickly symptoms worsen over time and when certain day-to-day milestones appear (such as falls, speech becoming hard to understand, bladder catheter use, and increasing mobility support). A smaller imaging study suggested that brain energy-use patterns change over time in ways that match clinical progression, but this evidence is less direct and comes from fewer people. [14] [15]

In a combined cohort of 555 people with MSA, median survival was 8.25 years, and later age at onset was linked to shorter survival. Higher scores on a standard symptom scale (Unified Multiple System Atrophy Rating Scale, UMSARS) at the start and faster UMSARS worsening over time both predicted poorer survival. [14]

Several real-world milestones signaled higher risk over time in the same cohort: repeated falls, speech becoming unintelligible, bladder catheter use, and needing medication for low blood pressure on standing were each linked to poorer survival in time-based analyses. Needing walking aids or a wheelchair (indoors or outdoors) was also tied to shorter survival at the 5-year mark, and respiratory infection was the most common reported cause of death. [14]

In a smaller retrospective study using a brain metabolism scan (FDG-PET), people with the parkinsonian subtype (MSA-P) showed worsening metabolism over time in areas including the putamen, while people with the cerebellar subtype (MSA-C) showed declines mainly in the cerebellum and frontal regions. The degree of metabolic decline tracked with worsening UMSARS scores, suggesting these scan changes moved alongside clinical progression in this dataset. [15]

One pathology-confirmed study comparing Parkinson's disease (PD), MSA, and progressive supranuclear palsy (PSP) found that a sustained, clear levodopa response was uncommon in MSA (8%) and did not relate to MSA milestones in that study. In contrast, in PD a clear long-term levodopa response was linked to fewer falls, lower dementia risk, and longer survival, highlighting that this marker had different meaning in PD than in MSA. [16]

For patients and caregivers, this research mainly helps explain which observable changes have been linked to shorter survival in groups of people with MSA, especially faster symptom worsening and the appearance of specific mobility, speech, and bladder milestones. The imaging work is more background for now: it suggests a way to measure progression with scans in research settings, but it is based on a small sample and does not yet establish how scans should be used for predicting an individual person's course. These studies describe patterns seen in groups and cannot precisely forecast what will happen for any one person. [14] [15] [16]

This review pooled evidence on how often pure autonomic failure (PAF) later develops into a brain-based alpha-synuclein condition such as multiple system atrophy (MSA), Parkinson's disease, or dementia with Lewy bodies. Overall, the pattern suggested that certain non-motor and early motor features can flag higher likelihood of later conversion, although results varied between studies in part because follow-up time differed. [17]

Across 900 people with PAF followed for about 6.4 years, 30% converted to a central alpha-synucleinopathy, including 12% who converted to MSA. The pooled overall conversion rate was 5.09 per 100 person-years. [17]

Certain symptoms were linked to higher conversion risk: acting out dreams during sleep (REM sleep behavior disorder) and subtle motor signs predicted conversion to any of the central alpha-synuclein conditions. Reduced sense of smell helped distinguish conversion toward Parkinson's disease compared with dementia with Lewy bodies or MSA. [17]

This evidence is most relevant for people diagnosed with pure autonomic failure and those trying to understand the range of possible long-term outcomes. It supports that some symptoms (dream-enactment sleep behavior, smell loss, subtle movement changes) can be clues that conversion risk is higher in groups, but it does not mean conversion will happen for a specific person, and it does not provide a precise timeline for an individual. [17]

Across these papers, the main pattern was that practical symptom-focused strategies and experimental disease-targeting approaches both showed mixed results. The clinical reports focused on blood pressure control and medication delivery when swallowing or gut movement is impaired, while the animal study tested a brain-directed genetic medicine strategy but did not achieve its main target. Overall evidence was early and limited by small sample sizes or single-patient reporting. [18] [19] [20]

In a randomized trial of 20 people with Parkinson's disease or multiple system atrophy who had both high blood pressure when lying down and low blood pressure on standing, sleeping with the whole bed tilted head-up improved several blood pressure measures linked to daytime function and standing. It did not lower nighttime systolic blood pressure, and people were less likely to stick with higher tilt angles (adherence fell to 60% at the highest angle tested). [18]

One case report described a person with advanced multiple system atrophy who could not absorb levodopa through the gut because of swallowing problems and slowed stomach movement. Giving co-beneldopa under the tongue was reported to bring rapid relief from severe motor "off" episodes and improve comfort in a palliative setting. Because this is one person, it is not clear how often this would work or how safe it would be in broader use. [19]

In an exploratory mouse study of a treatment designed to lower alpha-synuclein, systemic delivery of a peptide-linked antisense drug increased measures related to myelin and increased oligodendrocyte cell counts in several brain regions. However, it did not reduce alpha-synuclein or phosphorylated alpha-synuclein buildup, and only about 5% of oligodendrocytes showed uptake of the drug, suggesting delivery to the intended cell type was limited. The study also reported reduced astrocyte activation in some regions, with less change in microglia. [20]

For patients and caregivers, this set of studies mainly adds context about two common care challenges in multiple system atrophy: managing difficult blood pressure swings and delivering symptom-relief medicines when swallowing or gut absorption is unreliable. The head-up tilt sleeping trial provides early, limited evidence that posture-based nighttime strategies may shift some morning and daytime blood pressure measures, but it did not improve nighttime systolic blood pressure and was harder to maintain at steeper angles. The under-tongue levodopa report describes a possible route used in one palliative-care situation, but it is not yet supported by larger studies. The mouse antisense study is background research toward future disease-targeting treatments, and it shows that getting the drug into the specific brain cells affected in multiple system atrophy may be a key unresolved hurdle. [18] [19] [20]

Across this month's papers, autonomic problems in multiple system atrophy (MSA) showed up in two ways: as measurable changes on specialized reflex testing, and as vulnerability to less common but important complications (severe infection with blood pressure collapse, and low blood sodium with unexplained fever). Overall, the research suggests these issues can be part of MSA, but the testing and case reports also show limits in how specifically they point to MSA versus related disorders. [21] [22] [23]

In a moderate-sized retrospective study of several autonomic synucleinopathies (including MSA), certain measures from the Valsalva maneuver and heart-rate variability differed between patients and healthy controls. However, the study found that measures of the sympathetic (blood-vessel and blood-pressure) side and the heart-rate (vagal) side did not match closely in the same person, and none of the measures could clearly separate pure autonomic failure from Parkinson disease with orthostatic hypotension or MSA. [21]

One case report described an 81-year-old man with advanced MSA who developed septic shock within hours after a suprapubic catheter procedure, along with gas-forming infection of the urinary tract, acute kidney injury, and a temporary need for medications to support blood pressure. The authors interpreted this as an example of how autonomic failure in MSA can make the body less able to maintain stable blood pressure during severe infection. [22]

Another case report described a 66-year-old woman with probable MSA-P (MSA with Parkinson-like symptoms) who developed low blood sodium due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) and also had a central (non-infectious) fever. Her fever improved with cooling measures and her sodium improved with fluid restriction and added salt, which the authors linked to possible hypothalamus involvement in MSA. [23]

For patients and caregivers, these papers mainly add context rather than changing care. Autonomic reflex testing may help document autonomic nervous system dysfunction, but this study suggests the results may not reliably distinguish MSA from certain related disorders on their own. The case reports underline that some people with MSA can develop serious complications outside of movement symptoms, such as severe urinary infections with major blood pressure instability, or low sodium with unexplained fever, but single-patient reports cannot tell how common these problems are or who is most at risk. [21] [22] [23]

Across this month's papers, multiple lines of research point to MSA involving stress inside brain support cells called oligodendrocytes, including how they handle misfolded alpha-synuclein, how they manage energy, and how inflammation may interact with these processes. The studies also show that MSA biology can look different depending on the model used (human tissue or mice), which is important when interpreting what may cause what. Overall, the direction is consistent: cell-level changes in protein handling, energy pathways, and immune signaling appear repeatedly, but the sequence of events is still uncertain. [24] [25] [26] [27]

One study mapped brain shrinkage patterns in an MSA mouse model to brain-wide gene activity and found that regions with more MRI-defined damage aligned with gene programs tied to oligodendrocyte biology, energy metabolism, and neuroinflammation. This supports the idea that the parts of the brain that deteriorate in MSA are linked to specific cellular pathways rather than only to neuron loss. Because this was a mouse study, it helps build a framework for mechanisms but cannot fully prove what happens in people. [25]

Complementing that, an analysis of postmortem human brain datasets highlighted two downregulated genes (ZDHHC20 and AK5) related to palmitoylation (a chemical modification that can affect how proteins behave), with the strongest signal in cerebellar white matter. The study suggested these changes connect to mitochondrial dysfunction and reduced energy metabolism, and it placed the gene signal mainly in oligodendrocytes using single-nucleus data. This adds a specific molecular handle on why oligodendrocytes and white matter may be vulnerable in MSA. [26]

Several papers focused on alpha-synuclein, the protein that forms abnormal clumps in MSA. A structural study showed alpha-synuclein fibrils taken from an MSA patient can replicate after being transmitted to a transgenic mouse, but the fibrils also adapt in the mouse while keeping key structural features. In plain terms, this supports using transmission mouse models to study MSA-like alpha-synuclein, while also warning that the exact shape of the clumps may shift between species. [24]

In a lab and mouse-model study, graphene quantum dots reduced alpha-synuclein fibril stability in a test tube, lowered phosphorylated alpha-synuclein inclusions in dopaminergic neurons, and reduced overall alpha-synuclein burden in an MSA mouse brain, alongside higher markers linked to autophagy (a cell cleanup pathway). The same work also found dose- and time-dependent toxicity and DNA damage responses in non-neuronal human fibroblast cells, highlighting that changing alpha-synuclein biology can come with cellular stress depending on dose and cell type. This is preclinical research and does not show how this would translate to people. [28]

Another brain-tissue study reported that CRYAB (a stress-related protein) was hypermethylated and located together with alpha-synuclein in affected oligodendrocytes. This links an epigenetic change (methylation) to the same cells that contain alpha-synuclein clumps, suggesting that oligodendrocytes in MSA may have altered stress responses at the gene regulation level. The summary did not include whether this change is a cause, a consequence, or both. [27]

Two blood-immune profiling studies in broader groups, rather than in MSA alone, suggest that immune signaling changes can be detected outside the brain, but patterns may vary by population and disease stage. In one cross-sectional study comparing Parkinson s disease, atypical parkinsonism (including MSA), and controls across Guadeloupe and Montreal, immune cell differences depended strongly on geography, with different cell types correlating with clinical severity at each site. In a separate cross-sectional study of isolated REM sleep behavior disorder (a condition that can precede Parkinson s disease, dementia with Lewy bodies, or MSA), people had lower interleukin-2 in blood and fewer resting CD4 T cells producing interleukin-2, interleukin-4, and interleukin-10, and lower interleukin-2 related to worse motor scores, but baseline interleukin-2 did not differ between those who later converted versus those who did not. [29] [30]

Finally, a single-patient case report described an MSA-mimic syndrome linked to two SYNJ1 gene variants, with laboratory work showing reduced synaptojanin-1 abundance for each variant. This does not explain most MSA, but it illustrates that some people who look clinically similar to MSA may have a different underlying cellular problem involving synaptic biology, reinforcing that MSA-like symptoms can arise from different mechanisms. Because it is one patient, it may not apply broadly. [31]

For patients and caregivers, these studies mainly add background on what may be going wrong inside cells in MSA: oligodendrocytes appear central, with repeated signals involving alpha-synuclein handling, energy and mitochondria-related pathways, and inflammation or immune changes. Most of the evidence here is exploratory, based on mouse models, lab work, or cross-sectional human datasets, so it cannot yet tell whether any single change is the starting trigger or a downstream effect. The structural and gene-expression work helps researchers compare models to human disease more carefully, and the blood-immune studies highlight that immune signals may differ by geography, population, or stage, which can complicate efforts to develop simple blood markers.